Format

Send to

Choose Destination
Int J Audiol. 2018 Dec;57(12):917-924. doi: 10.1080/14992027.2018.1514537. Epub 2018 Nov 1.

Negative hearing effects of a single course of IV aminoglycoside therapy in cystic fibrosis patients.

Author information

1
a CEO Oricula Therapeutics LLC , Seattle , WA , USA.
2
b Department of Surgery , University of California San Diego , La Jolla , CA , USA.

Abstract

OBJECTIVE:

Identify hearing effects of a single course of intravenous (IV) aminoglycoside antibiotics (AGs) therapy in adult cystic fibrosis (CF) patients. Determine whether the change is large enough to enable a proof-of-concept study of a new drug preventing AG-associated hearing loss.

DESIGN:

Retrospective case review of CF patients with sequential audiograms ± an intervening course of IV AG therapy.

STUDY SAMPLE:

84 patients with no intervening IV AG treatment, 38 patients undergoing a single course of IV AGs.

RESULTS:

Using ASHA ototoxicity metrics, 45% of adult CF patients in the Single-IV group met the criteria for ototoxicity compared to 23% of the No-IV patients. Other hearing metrics including the average maximal threshold shift (TS) and average high frequency TS showed highly significant differences between groups. Testing only participants with mild or greater pre-therapy high frequency hearing loss further increased the differences between the two groups by every metric tested.

CONCLUSION:

Adult CF patients exposed to a single course of IV AGs have significantly greater TS than patients without IV AG exposure. Patients with mild to moderate hearing loss prior to AG-IVs are at increased risk of developing ototoxicity from subsequent parenteral AG therapy.

KEYWORDS:

Ototoxicity; aminoglycoside; audiogram; cystic fibrosis; hearing loss

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center